Hepion Pharmaceutical's Lead Drug Shows Antifibrotic Effects In Animal Studies
Hepion Pharmaceutical's Lead Drug Shows Antifibrotic Effects In Animal Studies
赫本製藥公司的先導藥物在動物研究中顯示出抗纖維化作用
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced positive results from an in vivo study of CRV431.
- In this study, the mouse model was treated for eight weeks with oral dosing of CRV431, or two comparator drugs, obeticholic acid, and elafibranor.
- Fibrosis was reduced by 47% with CRV431, 35% with obeticholic acid, and 37% with elafibranor, relative to vehicle controls.
- The company says that the results highlight a relatively short course of CRV431 treatment that can exert beneficial effects at an advanced stage of liver disease.
- Price Action: HEPA shares trading 0.89% higher at $2.12 in market hours on the last check Tuesday.
- 在這項研究中，小鼠模型被口服CRV431或兩種對照藥物，乙酰膽酸和Elafibror治療8周。
- 與賦形劑對照組相比，服用CRV431的患者纖維化程度降低了47%，服用乙酰膽酸的患者減少了35%，服用Elafibror的患者減少了37%。
- 該公司表示，這一結果突顯了CRV431治療療程相對較短，可以在肝病晚期發揮有益作用。
- 價格行動：週二最後一次檢查時，HEPA股價在市場時段上漲0.89%，至2.12美元。